ACRS Stock | | | USD 4.07 0.25 6.54% |
Founder
Mr. Frank Ruffo CPA is CoFounder, Chief Financial Officer of the Company since July 2012. From January 2014 to December 2015, Mr. Ruffo served parttime as a financial consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Mr. Ruffo also served parttime as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from 2011 to 2014 and the Chief Financial Officer of BioLeap, Inc. from 2010 to 2013. Prior to joining our company, Mr. Ruffo cofounded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Prior to joining Vicept Therapeutics, Inc., from 1996 to 2008, Mr. Ruffo served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc. He is a certified public accountant in Pennsylvania since 2016.
Age | 58 |
Tenure | 8 years |
Address | 701 Lee Road, Wayne, PA, United States, 19087 |
Phone | 484 324 7933 |
Web | https://www.aclaristx.com |
Ruffo received his B.S. degree in business administration with a major in accounting from LaSalle University.
Aclaris Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.1939) % which means that it has lost $0.1939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.2583) %, meaning that it created substantial loss on money invested by shareholders. Aclaris Therapeutics' management efficiency ratios could be used to measure how well Aclaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.47 in 2024.
Return On Capital Employed is likely to drop to -0.61 in 2024. At this time, Aclaris Therapeutics'
Non Current Assets Total are comparatively stable compared to the past year.
Total Current Assets is likely to gain to about 139.1
M in 2024, whereas
Other Current Assets are likely to drop slightly above 7.2
M in 2024.
Aclaris Therapeutics currently holds 426
K in liabilities with Debt to Equity
(D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Aclaris Therapeutics has a current ratio of 15.67, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Aclaris Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
Found 1 records | FOUNDER Age |
| BA MD | Oric Pharmaceuticals | 65 |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. Aclaris Therapeutics (ACRS) is traded on NASDAQ Exchange in USA. It is located in 701 Lee Road, Wayne, PA, United States, 19087 and employs 86 people. Aclaris Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.
Management Performance
Aclaris Therapeutics Leadership Team
Elected by the shareholders, the Aclaris Therapeutics' board of directors comprises two types of representatives: Aclaris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aclaris. The board's role is to monitor Aclaris Therapeutics' management team and ensure that shareholders' interests are well served. Aclaris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aclaris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neal DO, President, CoFounder | |
| Frank Ruffo, CFO CoFounder | |
| Joseph Monahan, Chief Officer | |
| Gail MD, Chief Officer | |
| Hugh Davis, President COO | |
| Steven PharmD, Head President | |
| Robert Doody, VP Relations | |
| MD DO, President CoFounder | |
| Matthew JD, General Secretary | |
| MD Frcp, Pres COO | |
| Kevin Balthaser, Chief Officer | |
| MD MBA, Senior Development | |
| Steve Tucker, Senior Leadership | |
| Ian Anderson, Ex RD | |
| Jon Jacobsen, Senior Chemistry | |
| James Loerop, Chief Officer | |
| Paul Changelian, VP Biology | |
Aclaris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aclaris Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to
measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.